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Abstract
Thyrotoxic periodic paralysis (TPP) is a medical emergency characterised by sudden onset of muscle
weakness with hypokalemia that resolves with the treatment of hyperthyroidism. We report three
cases of thyrotoxic periodic paralysis seen at the Accident and Emergency Care Department,
University of Malaya Medical Centre in a period of four months. We also review the clinical
presentation, pathophysiology, biochemical features and management of TPP. All three patients were
young Asian males, presenting with muscle weakness of sudden onset. The first patient presented
with lower limb weakness and had symptoms of thyrotoxicosis and goitre. He had a previous similar
episode which resolved spontaneously. The second patient presented with quadriplegia, respiratory
acidosis and had no signs and symptoms of thyrotoxicosis. The electrocardiogram of this patient
showed normal sinus rhythm with U wave in V3 and a flat T wave, which are characteristic of
hypokalaemia. The third patient, who was a known case of thyrotoxicosis, was admitted thrice for
hypokalemic paralysis during the study period. All cases had low serum potassium, suppressed TSH
and elevated T4 confirming thyrotoxic periodic paralysis. Potassium therapy was useful during the
crisis; however prophylactic potassium has not been shown to prevent attacks as seen in one of our
cases. Conclusion: Thyrotoxic periodic paralysis should be considered in the differential diagnosis
of sudden onset paralysis in young male patients. Determination of the plasma potassium levels and
thyroid hormones help in the diagnosis. The definitive treatment for TPP is the achievement of
euthyroid state.
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INTRODUCTION
Hypokalaemic paralysis is a rare cause of acute
weakness with a familial predisposition or in
association with other diseases. Hyperthyroidism
is one of the diverse underlying causes of
hypokalaemic paralysis. Thyrotoxic periodic
paralysis (TPP) is characterised by hypokalaemia,
and progressive symmetrical weakness leading
to paralysis of the proximal muscles especially
the shoulder and the pelvic girdle. Although the
incidence is higher in the Asian population, it
has been reported in other ethnic groups. We
review the clinical characteristics,
pathophysiology, biochemical features and
management of three cases of TPP presenting at
the Accident and Emergency Care Department
(A/E), University of Malaya Medical Centre
(UMMC) in a period of four months (September
2002 to December 2002).
CASE REPORTS
Case 1
A 21-year-old Chinese male, university student
presented at dawn to the Emergency Department
with sudden onset of lower limb weakness, and
inability to walk after he awoke from sleep. He
had a similar episode the previous day, which
resolved spontaneously after an hour. His vital
signs were blood pressure 110/70 mmHg; pulse
100 beats per minute and respiratory rate 18
breaths per minute.
Clinically, he had a diffusely enlarged goitre
with bruit.  His hands were warm and moist with
fine tremor and no exophthalmos. On
neurological examination, the strength of the
proximal muscles in both the lower limbs was
graded as 1/5 with reduced deep tendon reflexes.
There was no impairment of sensory function;
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cranial nerves were normal and there was no
incontinence of urine or faeces. Initial electrolyte
analysis showed the potassium level to be 2.4
mmol/L. Other electrolytes, urea, creatinine and
glucose were within the reference range. The
levels of calcium, magnesium, and phosphate
were normal.  The free T4 was found to be
elevated (92.3 pmol/L) and TSH was low
(< 0.02 uIU/ml), thereby confirming the
diagnosis of hypokalaemia due to thyrotoxicosis.
Case 2
A 36-year-old Thai male, a construction worker,
presented to the Emergency Department at 2 am
with weakness of the lower limbs and severe
shoulder pain of sudden onset. Clinically, the
patient was alert, conscious and cranial nerves
were intact. There was no stridor and no urinary
or faecal incontinence. Vital signs were normal.
Neurological examination revealed marked
muscle weakness of the proximal muscles in
both lower and upper limbs, reduced deep tendon
reflexes but with no sensory loss. There were no
signs and symptoms suggestive of thyrotoxicosis.
However, the laboratory data indicated that the
patient had marked hypokalaemia (1.8 mmo/L)
and increased level of creatine kinase (381 IU/
L). The ECG showed normal sinus rhythm and
U wave in V3 and a flat T wave. The arterial
blood gas analysis indicated respiratory acidosis.
Thyroid function test (free T4-66.8 pmol/L and
TSH < 0.02 uIU/ml) confirmed that the patient
was hyperthyroid. All the other biochemical
investigations were unremarkable.
Case 3
A 27-year-old Malay male  presented to the A/
E department with weakness of the lower limbs.
He was a known case of thyrotoxicosis and was
on treatment for the same. He had obvious signs
and symptoms and a family history of
thyrotoxicosis. During the study period, he was
admitted on three occasions to the hospital with
a similar complaint. His potassium levels during
his admissions were noted to be low (2.2, 2.4
and 2.7 mmol/L respectively) and free T4 levels
were 59.3, 45.8 and 42.6 pmol/L and TSH was
<0.02 uIU/L, thereby confirming that he had
TPP during his three admissions.
Treatment
All 3 patients were treated with intravenous
potassium. Once the potassium levels were
normalised, they were started on oral potassium
replacement therapy and were discharged within
three days of admission with anti-thyroid drugs.
DISCUSSION
Hypokalaemic paralysis represents a
heterogeneous group of disorders with a common
clinical presentation - acute weakness or paralysis
affecting the neuromuscular system. The causes
include “familial hypokalaemic paralysis,”
thyrotoxic periodic paralysis, renal tubular
acidosis, barium poisoning, primary
aldosteronism and gastro-intestinal potassium
losses. The approach to the diagnosis of patients
with hypokalaemic paralysis includes a vigorous
search for the underlying aetiology and the
management is potassium replacement therapy
as well as treatment of the underlying condition.
Clinical presentation
Thyrotoxic hypokalemic paralysis is a rare
complication of thyrotoxicosis. Rosenfeld first
described the link between hyperthyroidism and
periodic paralysis in 1902. Although the
incidence of TPP is reported to be higher among
Asians, it has been reported in other ethnic
groups.1  While thyrotoxicosis affects females
predominantly, the incidence of TPP is more
common in males. The age of onset is usually in
the 3rd to 5th decades of life. Paralysis tends to
occur on awakening, after exercise or following
consumption of a high carbohydrate meal.2
The flaccid paralysis is more prominent in
the lower extremities than in the upper limbs3
and is usually bilateral. Proximal muscles are
affected more often than the distal muscle groups
and the same clinical presentation was observed
in all our 3 cases. Rarely, the presentations
could be similar to that of upper motor neuron
disorder or respiratory dysfunction.4,5 Sensory
function is not altered in TPP. Deep tendon
reflexes can be diminished or absent; reduced
deep tendon reflex was noted in two of the
cases. In one of the patients, respiratory acidosis
was diagnosed by arterial blood gas analysis and
this indicated weakness of the respiratory
muscles.
The main biochemical abnormalities during
the paralysis are high levels of thyroid hormones
and hypokalaemia. The hypokalaemia is not due
to depletion of the body potassium but due to
intracellular shift of the potassium.6  Apart from
hypokalaemia, hypophosphataemia has been
reported during an attack of TPP.7
Hypophosphataemia could also be explained by
an intracellular shift of phosphate.7 Upon
resolution of paralysis, the phosphate level
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returns to normal. We did not observe any
decrease in phosphate levels in any of our cases.
Electrocardiograph manifestations may
include typical features of hypokalaemia; this
includes U waves (in leads V2 to V4), flattened
T waves, and QT prolongation.8 Apart from this,
disturbances in rate and rhythm may occur
including sinus tachycardia, atrial flutter, atrial
fibrillation, atrial and ventricular extra-systoles
and rarely ventricular fibrillation.9
The factors that precipitate TPP attack include
ingestion of a high carbohydrate diet and
strenuous exercise followed by rest.2 Attacks
can also be precipitated by alcohol ingestion,
emotional stress and medications such as
diuretics and insulin.3  The attacks are noted to
have a seasonal incidence, occurring more
commonly in warmer months compared to colder
months.2
Pathophysiology
The mechanism of TPP remains unclear. It is
probably due to increased activity of Na-K-
ATPase.10,11  It has been shown that excessive
thyroid hormones can induce increased
permeability of the muscle membrane to
electrolytes, with influx potassium into cells
associated with failure in depolarisation.
The aetiological factors associated with
hypokalaemic paralysis in TPP patients include
hyperthyroidism,11 genetic and racial
predisposition, exaggerated insulin response,12
hyper-adrenergic state,13 and probably other
mechanisms leading to intracellular shift of
potassium and phosphate. Studies have shown
that insulin response to meals is markedly higher
in the evening compared to the response in the
morning.14 This may possibly explain the
nocturnal preponderance of TPP.
Genetics
Periodic paralysis, without a familial
background, manifests only in the thyrotoxic
patient. A study of HLA haplotypes in Japanese
men with TPP, suggested that the HLA-DRW8
gene itself may play a significant role in the
susceptibility of TPP.15   In another study, HLA
antigens A2BW22 and AW19B17 were found
in Chinese patients.16  In black men, neither of
these haplotypes has been observed. Although
the HLA system has been suggested to provide
a link to an immunogenic aetiology, it seems to
be an unlikely explanation because in patients
with TPP, thyrotoxicosis need not be due to an
autoimmune mechanism.
The first genetic defect in TPP was identified
by Dias Da Silva et al.  A mutation was found in
KCNE3, the potassium ionic channel gene.17
They identified the R83H mutation in KCNE3
gene, the potassium ionic channel gene. It is
clear that more studies are required to identify
the basic genetic defect that is responsible for
TPP in thyrotoxic patients and to delineate the
mechanism underlying hypokalaemic paralysis.
Treatment
The treatment of TPP is administration of
potassium to hasten the recovery of the paralysis
and to avoid the associated cardiac complications
of hypokalemia.  In TPP, total body potassium
levels are unaltered, unlike that of FHP, and
hence aggressive potassium therapy may cause
a “rebound” hyperkalaemia. Lin SH, et al. used
propranolol to reverse paralysis, hypokalemia
and hypophosphataemia. Propranolol down-
regulates Na-K-ATPase activity.18 Generally,
patients are prescribed oral supplemental
potassium to avoid recurrence of the paralysis.
However, it has been proven to be ineffective in
the prevention of recurrence,19 a finding we
observed in one of our patients. In some cases,
spironolactone is used to prevent the paralysis.2
Both spironolactone and beta adrenergic blockers
have been reported to reduce the frequency of
attacks.2  This may be an effective treatment
while waiting for the patient to achieve euthyroid
status.
The definitive therapy for TPP is the
achievement of euthyroid state by medical,
surgery or radioactive iodine therapy. The
resolution of periodic paralysis occurs with the
restoration of euthyroidism. After initiating the
definitive treatment for thyrotoxicosis, patients
should be advised to avoid the known
precipitating factors.
CONCLUSION
Thyrotoxic periodic paralysis should be
considered as one of the differential diagnosis
when Asian males present with muscle weakness
soon after awakening. Hypokalemia is the most
consistent electrolyte abnormality in TPP.
Although the pathogenesis of this condition is
still not clear, there is strong evidence that
complete resolution occurs following successful
treatment of the thyroid dysfunction. Therefore,
it is imperative that the attending physician
recognises the characteristic clinical features of
TPP and distinguishes it from other similar
forms of paresis. The definitive treatment is to
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treat the thyrotoxicosis. Propranolol and
spironolactone can be used to prevent the
paralytic attacks. Oral supplemental potassium
is not effective in preventing the relapse.
Potassium is useful mainly to hasten the recovery
and prevent cardiac arrhythmias during the
attack.
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